Great to see more news, palatability of the drug should not be an issue at this next phase but from the next one so there is still time for the capsules to be produced. I am extremely positive on this company but I would caution that there is no garuntee that there will be a greater reduction in the cancer marker on the next dosage it may just be the same level of reduction. However a consistent finding all the way through in the reduction of certain cancer markers should be enough to see a significant change in PAA's fortunes.
Ann: Approval of Dose Escalation of PPL-1 in Human Trial, page-12
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
-0.015(7.50%) |
Mkt cap ! $95.88M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 18.5¢ | $106.2K | 550.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 714303 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 26750 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |